AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 13.7% in October

AstraZeneca PLC (OTCMKTS:AZNCF) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 42,200 shares, a growth of 13.7% from the October 15th total of 37,100 shares. Based on an average daily trading volume, of 2,500 shares, the short-interest ratio is presently 16.9 days.

AstraZeneca Stock Performance

OTCMKTS:AZNCF opened at $127.96 on Monday. AstraZeneca has a 12-month low of $118.16 and a 12-month high of $175.00. The stock’s fifty day simple moving average is $148.69 and its 200-day simple moving average is $155.30.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AstraZeneca stock. Eagle Bay Advisors LLC purchased a new position in AstraZeneca PLC (OTCMKTS:AZNCF) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,001 shares of the company’s stock, valued at approximately $156,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.